MUCIPLIQ is a nanopolymer engineered to mimic glycosaminoglycans such as heparan sulfates. Glycosaminoglycans are involved 1) in the stabilization of cells micro-environment, known as extracellular matrix, by binding to structural proteins, and 2) in cells communication process by protecting growth factors. At the site of a lesion, glycosaminoglycans are degraded, thereby the extracellular matrix is disorganized and the tissue is destroyed. By replacing damaged glycosaminoglycans, MUCIPLIQ provides a protection, and restores the matrix scaffold and cells communication, a process known as Matrix Therapy.

The purpose of this new controlled study is to determine whether MUCIPLIQ can decrease the incidence and the severity of radio-chemotherapy-induced mucositis in patients suffering of upper aerodigestive tract cancers, when used as a preventive agent.

The study's main hypothesis is that MUCIPLIQ mouthwash applications before radiotherapy would protect the healthy oral tissue against cytotoxic effect of chemotherapy and radiations.

Inclusion Criteria:

• Patient suffering from an upper aerodigestive tract carcinoma treated by radiotherapy alone or radiotherapy associated with a concomitant platine-salts-based chemotherapy ;
• Patient suffering of an upper aerodigestive tract carcinoma without entrance or located in the oral cavity, in the oropharynx or in the rhinopharynx ;
• Patient age of 18 years old or higher ;
• Writing informed consent to participate to the trial ;
• Patient affiliated to the French social security system.

Exclusion Criteria:

• Treatment by non-standard fragmentation (concentrate irradiation)
• Carcinoma located in the hypopharynx or in the larynx ;
• Known hypersensitivity to heparinoids ;
• Patient who already benefited from a radiotherapy treatment ;
• Patient who already benefited from a chemotherapy treatment. Patients who benefited from neoadjuvant chemotherapy as part of their upper aerodigestive tract carcinoma care, may be included if it was held at least 4 weeks before the inclusion visit ;
• Patient participating to another biomedical research ;
• Pregnant woman, breastfeeding woman, parturient or likely to be ;
• Patient deprived of freedom, under supervision or guardianship ;
• Patient unable to attend to scheduled medical monitoring due to geographical, social or mental reasons